ATLANTA, March 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 33rd Annual Healthcare Conference. The Company's virtual fireside chat is scheduled to begin at 3:20 p.m. ET on March 14, 2023.
A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.
About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stents and stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.
Contacts: | |
Artivion D. Ashley Lee Executive Vice President and Chief Financial Phone: 770-419-3355 | Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 332-895-3222 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$26.47 |
| Daily Change: | -0.14 -0.53 |
| Daily Volume: | 79,825 |
| Market Cap: | US$1.110B |
October 10, 2024 August 08, 2024 February 15, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
